Neurodegeneration: the role of EVs

Extracellular vesicles (EVs) were once dismissed as cellular debris. Over the past two decades they have become recognised as a fundamental channel of intercellular communication, and nowhere has that shift been more consequential than in the study of neurodegeneration. Neurons release EVs that carry proteins, lipids and RNA to neighbouring cells.  In the diseased brain, that same machinery appears to be hijacked to spread the very proteins that drive degeneration. At the same time, EVs that escape into blood and cerebrospinal fluid offer a tantalising window onto the brain, one of the few ways to sample neuronal biology without a biopsy. This dual identity, as both a vehicle of pathology and a source of biomarkers, has made neuron-derived extracellular vesicles one of the most active areas in neuroscience.

This article explains what neuronal EVs are, how they contribute to the spread of Alzheimer's, Parkinson's and other neurodegenerative diseases, why they are such promising (and contested) biomarkers, and what they are teaching us about disease mechanisms. It also covers the practical reality of working with these vesicles: the neuronal culture systems that generate them, and the isolation and characterisation tools needed to study them rigorously.

What Are Neuron-Derived Extracellular Vesicles (NDEVs)?

Extracellular vesicles are membrane-bound particles that virtually all cells secrete. They fall broadly into two classes: small exosomes (roughly 30 to 150 nm), which form inside multivesicular bodies and are released when those compartments fuse with the plasma membrane, and larger microvesicles (or ectosomes), which bud directly from the cell surface. Both carry a cargo of proteins, lipids, messenger RNA and microRNA that reflects the state of the cell that produced them, and both can deliver that cargo to recipient cells, altering their behaviour.

In the central nervous system, EVs are produced by every major cell type: neurons, astrocytes, microglia and oligodendrocytes. Neuron-derived extracellular vesicles are of particular interest because they report directly on the cells that are lost in neurodegenerative disease and because neuronal EV release is regulated by synaptic activity, tying vesicle secretion to the functional state of neural circuits. The challenge, as discussed below, is that once EVs from different cell types mix together in a biofluid, telling neuronal vesicles apart from the rest is far from trivial.

EVs as Vehicles of Pathology Spread in Neurodegeneration

A defining feature of most neurodegenerative diseases is that pathology does not appear everywhere at once. It begins in a vulnerable region and then propagates along anatomically connected pathways, as though the disease were being transmitted from cell to cell. Misfolded, aggregation-prone proteins are central to this process, and a growing body of evidence implicates extracellular vesicles as one of the routes by which these proteins move between neurons.

In Alzheimer's disease, both of the hallmark pathological proteins travel in EVs. Exosomes carrying toxic amyloid-beta oligomers can transfer pathology between cells and accelerate aggregation in recipient neurons, and neuron-derived exosomal tau has been shown to be toxic to recipient neurons after injection into mouse brain. EVs therefore offer a mechanism that helps explain the stereotyped, network-based spread of tau tangles and amyloid pathology that pathologists have long observed.

In Parkinson's disease and dementia with Lewy bodies, the relevant protein is alpha-synuclein. Aggregated alpha-synuclein is packaged into small EVs and transferred between neurons, and from neurons to glia, in cycles of release and uptake that seed further aggregation in receiving cells. Brain-derived exosomes from dementia with Lewy bodies have been shown to propagate alpha-synuclein pathology when introduced into recipient systems, reinforcing the idea that vesicular transfer is one engine of disease progression. Similar mechanisms have been proposed for TDP-43 and other proteins in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and for mutant huntingtin in Huntington's disease.

Neuron-Derived EVs as Blood Biomarkers

If neuronal EVs leak into the bloodstream carrying a faithful snapshot of neuronal pathology, they could provide something neurology has lacked: an accessible, repeatable, minimally invasive readout of what is happening in the brain. This is the promise that has driven intense interest in NDEV biomarkers. Because blood is far easier and safer to sample than cerebrospinal fluid, a validated blood test based on neuronal EVs could transform early diagnosis and the monitoring of disease and treatment.

Parkinson's disease has been a focal point. Work isolating neuron-derived EVs from blood has detected pathological, seeding-competent alpha-synuclein that distinguishes patients from controls, and serum measurements of EV-associated alpha-synuclein have been able to flag individuals at high risk of prodromal Parkinson's before motor symptoms appear and to identify a large fraction of those who later convert to a clinical diagnosis. Comparable efforts target amyloid-beta and phosphorylated tau in Alzheimer's, and EV-associated tau and TDP-43 as diagnostic markers in FTD and ALS. The common thread is that EVs concentrate and protect their cargo, potentially raising the signal of brain-derived proteins above the noise of the much larger pool of free protein in blood.

The L1CAM Problem: Why Isolation and Marker Choice Matter

The NDEV biomarker field carries an important cautionary tale. For years, the neural adhesion molecule L1CAM was used as the capture marker to immuno-isolate "neuron-derived" EVs from blood, on the assumption that L1CAM sits on the surface of neuronal vesicles. That assumption has been seriously challenged: careful biochemical work reported that L1CAM in plasma and cerebrospinal fluid is largely present as a free, soluble protein rather than bound to EVs, casting doubt on whether L1CAM immunocapture truly enriches neuronal vesicles at all. Subsequent studies have continued to debate the point, with some groups finding a small but real EV-associated L1CAM fraction.

The episode matters far beyond one marker. It illustrates that conclusions about neuronal EVs are only as good as the methods used to isolate and define them. A biomarker that turns out to be measuring free protein rather than vesicular cargo can produce results that fail to replicate across laboratories. This is why the field has converged on rigorous, standardised practice: characterising particles by size and concentration, confirming EV identity with accepted markers, controlling for non-vesicular contaminants, and reporting methods transparently under community frameworks such as the MISEV guidelines. For any group entering neuronal EV research, the lesson is that isolation method, purity assessment and characterisation are not afterthoughts; they are the foundation on which every downstream claim rests.

Tools for Isolating and Characterising Neuronal EVs

Once healthy neuronal cultures are producing EVs, the next requirement is to isolate and characterise those vesicles reliably, the very step where the L1CAM episode shows how much rests on good method. Cell Guidance Systems offers a complementary set of tools spanning the workflow. Exo-spin size-exclusion chromatography columns separate intact EVs from soluble protein gently, preserving vesicle integrity for downstream analysis, while EVlution TFF tangential flow filtration supports larger or more concentrated preparations. For quality control, the NTA size profiling service measures particle size distribution and concentration by nanoparticle tracking analysis, providing the characterisation data that rigorous EV reporting requires. Together these address the practical bottleneck that determines whether neuronal EV findings will hold up.

Toward Reproducible Neuronal EV Research

Neuronal extracellular vesicles sit at the intersection of two of the most important questions in neurology: how pathology spreads through the brain, and how we can detect that pathology early and non-invasively. The evidence that EVs carry amyloid-beta, tau, alpha-synuclein and other aggregation-prone proteins between neurons gives a mechanistic handle on disease progression, while the presence of neuron-derived EVs in blood opens a route to biomarkers that has been pursued for Parkinson's, Alzheimer's, ALS and FTD. The field's main vulnerability, as the L1CAM marker debate makes clear, is methodological: results are only as trustworthy as the neuronal cultures that generate the vesicles and the isolation and characterisation steps that define them. Reproducible neuronal EV research therefore rests on stable, well-supported neuronal models and on gentle, well-characterised EV preparation, the practical foundations on which the biology depends.

Cell Guidance Systems Products and Services for Neuronal EV Research

Neurotrophic Growth Factors. For neuronal culture and differentiation, Cell Guidance Systems supplies a comprehensive range of recombinant growth factors, including neurotrophic factors such as BDNF, GDNF, NGF and NT-3 for survival, differentiation and neurite outgrowth.

PODS Growth Factors. For sustained, controlled delivery in long-term neuronal and organoid culture, our PODS growth factors encapsulate bioactive proteins in a stable protein co-crystal that releases active factor over an extended period from a single application, reducing feeding frequency and improving consistency. The range includes PODS-formatted BDNF, GDNF and many other factors relevant to neuronal work, in both human and other-species formats. For factors outside the standard catalogue, the Custom PODS Proteins service develops sustained-release formulations of your protein of interest.

EV Isolation and Characterisation. Exo-spin size-exclusion columns and EVlution TFF tangential flow filtration provide gentle, scalable EV purification, and the NTA size profiling service delivers particle size and concentration data for EV characterisation. Our full EV and exosome services support projects from isolation through analysis.

PODS Technology and Resources. For application notes, technical guides and peer-reviewed publications on using PODS in neuronal and 3D culture, see our PODS resources page and the PODS depot growth factors technology overview.

References

[1] Thompson AG, Gray E, Heman-Ackah SM, et al. Extracellular vesicles in neurodegenerative disease: pathogenesis to biomarkers. Nat Rev Neurol. 2016;12(6):346-357.

[2] Watson LS, Hamlett ED, Stone TD, Sims-Robinson C. Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer's disease. Mol Neurodegener. 2019;14(1):22.

[3] Sardar Sinha M, Ansell-Schultz A, Civitelli L, et al. Alzheimer's disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathol. 2018;136(1):41-56.

[4] Winston CN, Aulston B, Rockenstein EM, et al. Neuronal exosome-derived human tau is toxic to recipient mouse neurons in vivo. J Alzheimers Dis. 2019;67(2):541-553.

[5] Ngolab J, Trinh I, Rockenstein E, et al. Brain-derived exosomes from dementia with Lewy bodies propagate alpha-synuclein pathology. Acta Neuropathol Commun. 2017;5(1):46.

[6] Kluge A, Bunk J, Schaeffer E, et al. Detection of neuron-derived pathological alpha-synuclein in blood. Brain. 2022;145(9):3058-3071.

[7] Yan S, Jiang C, Janzen A, et al. Neuronally derived extracellular vesicle alpha-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol. 2024;81(1):59-68.

[8] Chen Z, Brodie MJ, et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat Med. 2024;30(6):1771-1783.

[9] Norman M, Ter-Ovanesyan D, Trieu W, et al. L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nat Methods. 2021;18(6):631-634.

[10] Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023). J Extracell Vesicles. 2024;13(2):e12404.

[11] Soucy JR, Oswald J, Kriukov E, et al. Sustained neurotrophic factor co-treatment enhances donor and host retinal ganglion cell survival in mice. Transl Vis Sci Technol. 2025;14(9):27.

[12] Chang H, Heuer R, Oleksijew A, et al. An engineered three-dimensional stem cell niche in the inner ear by applying a nanofibrillar cellulose hydrogel with a sustained-release neurotrophic factor delivery system. Acta Biomater. 2020;108:111-127.

IMAGE Dopamine levels in PD brains of patients receiving cell therapy treatment at baseline, 12 and 18 months CREDIT Tabar et al (Creative Commons)